yttrium has been researched along with Neuroendocrine Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagni, O; Cianni, R; Filippi, L; Pelle, G; Salvatori, R; Schillaci, O; Scopinaro, F | 1 |
| Bloomston, M; Schmidt, C; Shah, MH | 1 |
1 review(s) available for yttrium and Neuroendocrine Tumors
| Article | Year |
|---|---|
Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies.
Topics: Cell Differentiation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Humans; Interferon-alpha; Ki-67 Antigen; Neuroendocrine Tumors; Octreotide; Tomography, Emission-Computed, Single-Photon; Yttrium | 2011 |
1 other study(ies) available for yttrium and Neuroendocrine Tumors
| Article | Year |
|---|---|
Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours.
Topics: Aged; Biomarkers, Tumor; Cohort Studies; Disease-Free Survival; Embolization, Therapeutic; Female; Gallium Radioisotopes; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Treatment Outcome; Yttrium | 2016 |